TACE and other ADAM proteases as targets for drug discovery.
暂无分享,去创建一个
M. Lambert | J. White | M L. Moss | J M. White | M H. Lambert | R C. Andrews | M. Moss | J. White | R. Andrews | M. Moss
[1] E. Engvall,et al. Binding of ADAM12, a Marker of Skeletal Muscle Regeneration, to the Muscle-specific Actin-binding Protein, α-Actinin-2, Is Required for Myoblast Fusion* , 2000, The Journal of Biological Chemistry.
[2] G. Rubin,et al. The cell surface metalloprotease/disintegrin Kuzbanian is required for axonal extension in Drosophila. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[3] T. Wolfsberg,et al. ADAMs in fertilization and development. , 1996, Developmental biology.
[4] P. Genever,et al. Localization of ADAM10 and Notch receptors in bone. , 1999, Bone.
[5] A Cumano,et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. , 2000, Molecular cell.
[6] H. Birkedal‐Hansen,et al. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[7] T. Oltersdorf,et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. , 1990, Science.
[8] C. Blobel,et al. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. , 1999, Journal of cell science.
[9] P. Slocombe,et al. Meltrin γ (ADAM-9) mediates cellular adhesion through α6β1 integrin, leading to a marked induction of fibroblast cell motility , 2000 .
[10] R. Huber,et al. Refined 2.0 A X-ray crystal structure of the snake venom zinc-endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin. , 1994, Journal of molecular biology.
[11] E. Meyer,et al. Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor α convertase inhibitors , 1998, Protein science : a publication of the Protein Society.
[12] E. Wagner,et al. Strain-dependent epithelial defects in mice lacking the EGF receptor. , 1995, Science.
[13] F. Loechel,et al. ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3* , 2000, The Journal of Biological Chemistry.
[14] E. Engvall,et al. Human ADAM 12 (Meltrin α) Is an Active Metalloprotease* , 1998, The Journal of Biological Chemistry.
[15] M. Lambert,et al. Specific Sequence Elements Are Required for the Expression of Functional Tumor Necrosis Factor-α-converting Enzyme (TACE)* , 1999, The Journal of Biological Chemistry.
[16] X. Zhang,et al. Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. , 1997, Bioorganic & medicinal chemistry.
[17] J. White,et al. Sequence-specific interaction between the disintegrin domain of mouse ADAM 3 and murine eggs: role of beta1 integrin-associated proteins CD9, CD81, and CD98. , 2001, Molecular biology of the cell.
[18] A. H. Drummond,et al. Recent advances in matrix metalloproteinase inhibitor research , 1996 .
[19] E. Kojro,et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] E. Nice,et al. Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation , 1993, Cell.
[21] D. Price,et al. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. , 1990, Science.
[22] G. Rubin,et al. Kuzbanian Controls Proteolytic Processing of Notch and Mediates Lateral Inhibition during Drosophila and Vertebrate Neurogenesis , 1997, Cell.
[23] P. Cohen,et al. Novel aspects of the insulin-like growth factor binding proteins. , 1999, Molecular genetics and metabolism.
[24] E. Engvall,et al. A Novel, Secreted Form of Human ADAM 12 (Meltrin α) Provokes Myogenesis in Vivo * , 1998, The Journal of Biological Chemistry.
[25] 2 Å X‐ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retro‐binding mode , 1997, FEBS letters.
[26] R. Derynck,et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.
[27] R. Huber,et al. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] T G Wolfsberg,et al. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell- matrix interactions , 1995, The Journal of cell biology.
[29] D. Bradshaw,et al. Metalloproteinases as Targets for Anti-Inflammatory Drugs , 1999, Progress in Inflammation Research.
[30] R. Black,et al. Unaltered Cleavage and Secretion of Angiotensin-converting Enzyme in Tumor Necrosis Factor-α-converting Enzyme-deficient Mice* , 1999, The Journal of Biological Chemistry.
[31] P. Glynn,et al. Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types. , 1996, The Biochemical journal.
[32] R. Black,et al. Functional Analysis of the Domain Structure of Tumor Necrosis Factor-α Converting Enzyme* , 2000, The Journal of Biological Chemistry.
[33] L. Bélec,et al. Increased tumor necrosis factor-alpha serum levels in patients with HIV wasting syndrome and euthyroid sick syndrome. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[34] F. Loechel,et al. Trafficking of human ADAM 12-L: retention in the trans-Golgi network. , 2000, Biochemical and biophysical research communications.
[35] R. Black,et al. ADAMs: focus on the protease domain. , 1998, Current opinion in cell biology.
[36] M. T. Brewer,et al. Identification and Characterization of a Pro-tumor Necrosis Factor-α-processing Enzyme from the ADAM Family of Zinc Metalloproteases* , 1997, The Journal of Biological Chemistry.
[37] R. Fässler,et al. The Cysteine-Rich Domain of Human Adam 12 Supports Cell Adhesion through Syndecans and Triggers Signaling Events That Lead to β1 Integrin–Dependent Cell Spreading , 2000, The Journal of cell biology.
[38] J. Fox,et al. Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d). , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[39] C. Blobel,et al. Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta. , 1999, The Biochemical journal.
[40] L. Lum,et al. Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, The Journal of Biological Chemistry.
[41] C. Blobel,et al. Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). , 2000, The Biochemical journal.
[42] R. Black,et al. Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. , 1999, Biochemical and biophysical research communications.
[43] P. Croucher,et al. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. , 1997, Biochemical and biophysical research communications.
[44] G. Devi,et al. Differential Effects of Insulin-Like Growth Factor (IGF)-Binding Protein-3 and Its Proteolytic Fragments on Ligand Binding, Cell Surface Association, and IGF-I Receptor Signaling* * This research was supported by US Army Grants DAMD17-991-9522 (to G.R.D.) and DAMD17-96-1-6204 and DAMD17-96-1-7204 (t , 2000, Endocrinology.
[45] R. Maciewicz,et al. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. , 1999, Journal of medicinal chemistry.
[46] P. Primakoff,et al. The ADAM gene family: surface proteins with adhesion and protease activity. , 2000, Trends in genetics : TIG.
[47] Y. Takada,et al. Specific Interaction of the Recombinant Disintegrin-like Domain of MDC-15 (Metargidin, ADAM-15) with Integrin αvβ3* , 1998, The Journal of Biological Chemistry.
[48] L. Liotta,et al. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[49] N. Hooper,et al. The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor‐α convertase , 1998, FEBS letters.
[50] Sudhir V. Shah,et al. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. , 2000, The Journal of clinical investigation.
[51] David C. Lee,et al. TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice , 1993, Cell.
[52] M. Overgaard,et al. Regulation of Human ADAM 12 Protease by the Prodomain , 1999, The Journal of Biological Chemistry.
[53] J. Martel-Pelletier,et al. IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis , 1998, Inflammation Research.
[54] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[55] Nicole Nelson,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.
[56] M. Lambert,et al. The Tumor Necrosis Factor-α Converting Enzyme , 2000 .
[57] J. White,et al. Sequence-specific Interaction between the Disintegrin Domain of Mouse ADAM 2 (Fertilin β) and Murine Eggs , 2000, The Journal of Biological Chemistry.
[58] N. Mckie,et al. The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. , 1998, Biochemical and biophysical research communications.
[59] Paul S. Charifson,et al. Practical Application of Computer-Aided Drug Design , 1997 .
[60] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[61] Raphael Kopan,et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. , 2000, Molecular cell.
[62] T. Wolfsberg,et al. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. , 1995, Developmental biology.
[63] A. H. Drummond,et al. Preclinical and Clinical Studies of MMP Inhibitors in Cancer , 1999, Annals of the New York Academy of Sciences.
[64] Joseph D. Buxbaum,et al. Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor* , 1998, The Journal of Biological Chemistry.
[65] D. Small,et al. Regulation of APP cleavage by α‐, β‐ and γ‐secretases , 2000 .
[66] Y. Nabeshima,et al. A metalloprotease-disintegrin participating in myoblast fusion , 1995, Nature.
[67] G. Wu,et al. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. , 1999, Journal of immunology.
[68] C. Blobel,et al. Interaction of the Metalloprotease Disintegrins MDC9 and MDC15 with Two SH3 Domain-containing Proteins, Endophilin I and SH3PX1* , 1999, The Journal of Biological Chemistry.
[69] S. Rose-John,et al. Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. , 2000, European journal of biochemistry.
[70] G. Weskamp,et al. MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains , 1996, The Journal of cell biology.
[71] David C. Lee,et al. An essential role for ectodomain shedding in mammalian development. , 1998, Science.
[72] G. Rubin,et al. KUZ, a Conserved Metalloprotease-Disintegrin Protein with Two Roles in Drosophila Neurogenesis , 1996, Science.
[73] Alfredo G. Tomasselli,et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.
[74] D. Sheppard,et al. RGD-independent Binding of Integrin α9β1 to the ADAM-12 and -15 Disintegrin Domains Mediates Cell-Cell Interaction* , 2000, The Journal of Biological Chemistry.
[75] R. Barbour,et al. Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.
[76] R. Black,et al. Stimulation-induced Down-regulation of Tumor Necrosis Factor-α Converting Enzyme* , 2000, The Journal of Biological Chemistry.
[77] A. Gaultier,et al. PACSIN2 is a regulator of the metalloprotease/disintegrin ADAM13. , 2000, Developmental biology.
[78] G. Weskamp,et al. Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity* , 1999, The Journal of Biological Chemistry.
[79] P. Rakic,et al. Processing of the notch ligand delta by the metalloprotease Kuzbanian. , 1999, Science.
[80] M. Ohashi,et al. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. , 1997, Life sciences.
[81] P. Slocombe,et al. Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility. , 2000, Journal of cell science.
[82] J. Buxbaum,et al. Tumor Necrosis Factor-α-converting Enzyme Is Required for Cleavage of erbB4/HER4* , 2000, The Journal of Biological Chemistry.
[83] Mark Whittaker,et al. Matrix metalloproteinase inhibitors 1998 , 1998 .
[84] A. Zolkiewska,et al. Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. , 2000, The Biochemical journal.
[85] J. Laydon,et al. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNFα processing , 1997, Inflammation Research.
[86] E. Mekada,et al. A metalloprotease–disintegrin, MDC9/meltrin‐γ/ADAM9 and PKCδ are involved in TPA‐induced ectodomain shedding of membrane‐anchored heparin‐binding EGF‐like growth factor , 1998, The EMBO journal.
[87] C. López-Otín,et al. ADAM 23/MDC3, a Human Disintegrin That Promotes Cell Adhesion via Interaction with the αvβ3 Integrin through an RGD-independent Mechanism , 2000 .
[88] A. Goate,et al. A common enzyme connects notch signaling and Alzheimer's disease. , 2000, Genes & development.
[89] M. Lambert,et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.
[90] R. Doms,et al. Protein Kinase C-dependent α-Secretase Competes with β-Secretase for Cleavage of Amyloid-β Precursor Protein in the Trans-Golgi Network* , 2000, The Journal of Biological Chemistry.
[91] J G Flanagan,et al. Regulated cleavage of a contact-mediated axon repellent. , 2000, Science.
[92] M. Gerhart,et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.
[93] S. Narula,et al. Purification of ADAM 10 from bovine spleen as a TNFα convertase , 1997 .
[94] T. Wolfsberg,et al. A potential fusion peptide and an integrin ligand domain in a protein active in sperm–egg fusion , 1992, Nature.
[95] A. Bernstein,et al. Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1 , 2000, Nature Cell Biology.